Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
J Am Acad Dermatol ; 45(6): 914-8, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11712039

ABSTRACT

We report the case of a 43-year-old male patient with persistent multifocal, skin-restricted, CD30-positive, large T-cell lymphoma. Combination therapy of systemic interferon alfa and oral bexarotene was initiated on an experimental basis in the hope of circumventing therapies such as methotrexate, radiotherapy, or multiple-agent chemotherapy that may be required in such cases. This treatment was associated with rapid and marked regression of the patient's cutaneous lesions.


Subject(s)
Anticarcinogenic Agents/administration & dosage , Antineoplastic Agents/administration & dosage , Interferon-alpha/administration & dosage , Ki-1 Antigen/analysis , Lymphoma, T-Cell, Cutaneous/drug therapy , Skin Neoplasms/drug therapy , Tetrahydronaphthalenes/administration & dosage , Administration, Oral , Adult , Bexarotene , Drug Therapy, Combination , Humans , Lymphoma, T-Cell, Cutaneous/pathology , Male , Skin Neoplasms/pathology
2.
BioDrugs ; 15(7): 431-7, 2001.
Article in English | MEDLINE | ID: mdl-11520254

ABSTRACT

Cutaneous T-cell lymphoma (CTCL) is most often a skin-infiltrating malignancy of clonal CD4+ T-cells. Therapy is based on staging and the likelihood of progression. Biological response modifiers and chemotherapeutic agents are used to preserve the integrity of the host antitumour response while selectively targeting the malignant cells. The biological response-modifying treatment options currently used to treat CTCL are bexarotene, denileukin diftitox, interferon-alpha, interferon-gamma and interleukin-12, as well as extracorporeal photopheresis and phototherapy. A combination therapy approach maximises response in patients with advanced CTCL. Biological response modifiers in combination with photopheresis are used for patients with the leukaemic phase of the disease. Among the majority of patients with advanced stage disease so treated, immune response augmentation appears to prolong survival. Future areas of research should assess not only survival and optimal treatment combinations, but also quality of life during the treatment period.


Subject(s)
Diphtheria Toxin , Immunologic Factors/therapeutic use , Interleukin-2 , Lymphoma, T-Cell, Cutaneous/drug therapy , Bexarotene , Humans , Interferon-alpha/therapeutic use , Interleukin-12/therapeutic use , Photopheresis , Phototherapy , Proteins/therapeutic use , Recombinant Fusion Proteins , Tetrahydronaphthalenes/therapeutic use
4.
J Am Acad Dermatol ; 43(5 Pt 1): 870-4, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11050599

ABSTRACT

An entity termed "pustular vasculitis of the hands" was recently described. Patients with this condition presented with low-grade fevers and erythematous plaques, pustules, and bullae limited to the dorsal hands and fingers, which were characterized histologically by a dense neutrophilic infiltrate and leukocytoclastic vasculitis. We describe patients with a similar clinical presentation, but who lacked vasculitis on biopsy findings. We describe 3 otherwise asymptomatic patients with hemorrhagic bullae, plaques, and pustules solely on the dorsal hands. Biopsy specimens showed a neutrophilic infiltrate and leukocytoclasis, but no necrotizing vasculitis, and were reminiscent of Sweet's neutrophilic dermatoses. In our patients, corticosteroids or dapsone led to clearing of the lesions, and small maintenance doses of dapsone prevented their recurrence. Our 3 patients had clinical lesions similar to those termed pustular vasculitis of the hands, but which lacked leukocytoclastic vasculitis on biopsy findings. Because of histologic findings and a therapeutic response more characteristic of Sweet's syndrome, we propose the term neutrophilic dermatosis of the dorsal hands. In addition, low-dose dapsone is proposed as a possible first-line therapy in this condition, especially in those with recurrent disease.


Subject(s)
Blister/pathology , Neutrophil Infiltration , Skin Diseases/pathology , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Dapsone/therapeutic use , Diagnosis, Differential , Female , Hand/pathology , Humans , Male , Middle Aged , Recurrence , Skin Diseases/drug therapy , Skin Diseases/immunology , Sweet Syndrome/diagnosis , Vasculitis
5.
J Investig Dermatol Symp Proc ; 4(1): 85-90, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10537015

ABSTRACT

Photopheresis is a leukapheresis-based therapy that utilizes 8-methoxypsoralen and ultraviolet A irradiation. Photopheresis is currently available at approximately 150 medical centers worldwide. Recent evidence suggests that this therapy used as a single agent may significantly prolong life, as well as induce a 50%-75% response rate among individuals with advanced cutaneous T cell lymphoma (CTCL). Furthermore, a 20%-25% complete response rate with photopheresis alone, or in combination with other biologic response modifiers, has been obtained at our institution among patients with Sezary syndrome. These complete responses have been characterized by the complete disappearance of morphologically atypical cells from the skin and blood. The use of sensitive molecular techniques has also confirmed the sustained disappearance of the malignant T cell clone from the blood of patients with complete responses. In addition to the treatment of CTCL, numerous reports indicate that photopheresis is a potent agent in the therapy of acute allograft rejection among cardiac, lung, and renal transplant recipients. Chronic graft versus host disease also appears to be quite responsive to photopheresis therapy. Likewise, there may also be a potential role for photopheresis in the therapy of certain autoimmune diseases that are poorly responsive to conventional therapy. The immunologic basis for the responses of patients with these conditions is likely due to the induction of anticlonotypic immunity directed against pathogenic clones of T lymphocytes. Treatment-induced apoptotic death of pathogenic T cells and activation of antigen presenting cells are postulated to have important effects in this therapeutic process.


Subject(s)
Photopheresis , Animals , Autoimmune Diseases/therapy , Graft Rejection/prevention & control , Humans , Lymphoma, T-Cell, Cutaneous/therapy , Skin Neoplasms/therapy
6.
J Cutan Pathol ; 25(8): 450-4, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9826172

ABSTRACT

Previous reports of a distinctive, fibrous, soft-tissue tumor include eight patients with subcutaneous lesions and six patients with intramuscular lesions. We report a 48-year-old woman with a 2-cm cutaneous and subcutaneous nodule on the left arm with the same histologic features. An excisional biopsy showed a large, well circumscribed tumor replacing the reticular dermis and subcutaneous tissue. The tumor was relatively hypocellular and composed primarily of large, spindled, plump or stellate fibroblasts haphazardly dissecting between thickened fibrotic collagen bundles. The stroma contained a large amount of mucin which was positive with alcian blue at pH 2.5, and relatively numerous mast cells were present. The fibroblastic-like cells were positive with Vimentin and Factor XIIIA and negative with S-100, desmin, actin and keratin.


Subject(s)
Fibroma, Desmoplastic/pathology , Skin Neoplasms/pathology , Collagen/analysis , Female , Fibroma, Desmoplastic/metabolism , Humans , Middle Aged , Skin/chemistry , Skin/pathology , Skin Neoplasms/metabolism , Transglutaminases/analysis , Vimentin/analysis
10.
J Cutan Pathol ; 21(5): 467-71, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7868760

ABSTRACT

Perifollicular fibroma is a cutaneous hamartomatous proliferation of the pilar connective tissue sheath. We describe a patient with multiple perifollicular fibromas and analyze the literature on this topic. Histologically, perifollicular fibroma is characterized by a concentric arrangement of collagen fibers surrounding a generally unaltered hair follicle. Clinically, it is usually multiple and occurs predominantly on the face and upper trunk. This clinical presentation is similar to that observed in patients with the Birt-Hogg-Dubé syndrome where, in addition to perifollicular fibromas, fibrofolliculomas, trichodiscomas, and acrochordons are found. Several reports of multiple perifollicular fibroma prior to the recognition of this syndrome may, in fact, represent cases of the Birt-Hogg-Dubé syndrome.


Subject(s)
Hamartoma/pathology , Skin Neoplasms/pathology , Adult , Female , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...